fulvene has been researched along with titanocene in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Claffey, J; Hogan, M; Pampillón, C; Tacke, M | 2 |
| Strohfeldt, K; Tacke, M | 1 |
1 review(s) available for fulvene and titanocene
| Article | Year |
|---|---|
Bioorganometallic fulvene-derived titanocene anti-cancer drugs.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cyclopentanes; Drug Screening Assays, Antitumor; Inhibitory Concentration 50; Kidney Neoplasms; LLC-PK1 Cells; Molecular Structure; Organometallic Compounds; Swine | 2008 |
2 other study(ies) available for fulvene and titanocene
| Article | Year |
|---|---|
Novel achiral titanocene anti-cancer drugs synthesised from bis-N,N-dimethylamino fulvene and lithiated heterocyclic compounds.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclopentanes; Drug Evaluation, Preclinical; Heterocyclic Compounds; Humans; Inhibitory Concentration 50; Molecular Conformation; Molecular Structure; Neoplasms; Organometallic Compounds | 2008 |
Synthesis and cytotoxicity studies of new morpholino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs.
Topics: Animals; Antineoplastic Agents; Cyclopentanes; Inhibitory Concentration 50; LLC-PK1 Cells; Morpholines; Organometallic Compounds; Structure-Activity Relationship; Swine | 2008 |